Agilent Technologies Purchases Resolution Bioscience in $550m Deal 

Agilent Technologies (SYSE: A), a $5.3b analytical instrumentation development and manufacturing company, is buying Resolution Bioscience, maker of a non-invasive liquid biopsy platform, for $550m upfront plus additional milestones of up to $145m.  Resolution Bioscience’s ctDx test can detect all four major types of genetic alterations known to drive cancers and has a turnaround time of a few days.

Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Diagnostics